Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.49 Mil Enterprise Value: 126.67 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 52/100

Lexicon Pharmaceuticals Inc INPEFA Call Transcript

May 30, 2023 / 12:00PM GMT
Release Date Price: €4.1
Operator

Good day, and welcome to Lexicon's INPEFA Approval Announcement Conference Call. (Operator Instructions) Please note this event is being recorded.

At this time, I would like to turn the conference over to Carrie Siragusa. Please go ahead.

Carrie Siragusa

Thank you, Allison. Good morning, and welcome to the Lexicon Pharmaceutical's INPEFA Approval Announcement Conference call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer; Jeff Wade, Lexicon's President and Chief Financial Officer; and Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer. On Friday afternoon, we issued a press release announcing the FDA approval of our NDA for sotagliflozin and heart failure now being launched under the brand name INPEFA. This press release is available on our website at www.lexpharma.com. A webcast of this call, along with the slide presentation is also available on our website. During this call, we will review the information provided in the release, provide an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot